3.07  0.29 (10.43%)		09-10 16:00
Open: 2.89 High: 3.25 Volume: 3,967,419		Pre. Close: 2.78 Low: 2.85 Market Cap: 20(M)

Short term
Mid term
Targets	6-month :	4.96	1-year :	6.38
Resists	First :	4.25	Second :	5.46
Pivot price	2.65
Supports	First :	2.27	Second :	1.89
MAs	MA(5) :	2.55	MA(20) :	2.8
	MA(100) :	3.45	MA(250) :	2.91
MACD	MACD :	-0.5	Signal :	-0.5
%K %D	K(14,3) :	29.1	D(3) :	20.5
RSI	RSI(14): 37.5
52-week	High :	9	Low :	1.46

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ MEIP ] has closed below upper band by 45.8%. Bollinger Bands are 68% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	2.74 - 2.75	2.75 - 2.77
Low:	2.52 - 2.53	2.53 - 2.55
Close:	2.66 - 2.68	2.68 - 2.7

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

Wed, 10 Sep 2025
MEI Pharma sheds biotech woes to rebrand as crypto company - Fierce Biotech

Sat, 23 Aug 2025
MEI Pharma's astonishing gamble: from a near-death pharmaceutical company to the "first Litecoin stock," has a new "money printer" been born on Wall Street? - ChainCatcher

Tue, 05 Aug 2025
MEI Pharma Invests in Litecoin as Primary Treasury Asset - San Diego Business Journal

Tue, 22 Jul 2025
MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange - Business Wire

Sun, 20 Jul 2025
MEI Pharma (MEIP) Becomes the First and Only Publicly Traded LTC Holder on a National Exchange - Yahoo Finance

Fri, 18 Jul 2025
MEI Pharma Announces $100M Placement To Initiate Litecoin Treasury Strategy: Retail Cheers Charlie Lee’s Addition To Company Board - Stocktwits

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	33 (M)
Shares Float	6 (M)
Held by Insiders	14.4 (%)
Held by Institutions	8.1 (%)
Shares Short	2,640 (K)
Shares Short P.Month	2,150 (K)

EPS	-4.75
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.93
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-23.3 %
Return on Equity (ttm)	-89.8 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-0.18
Sales Per Share	0
EBITDA (p.s.)	-0.51
Qtrly Earnings Growth	0 %
Operating Cash Flow	-36 (M)
Levered Free Cash Flow	-15 (M)

PE Ratio	-0.57
PEG Ratio	0
Price to Book value	0.91
Price to Sales	0
Price to Cash Flow	-2.42

Dividend	1.75
Forward Dividend	0
Dividend Yield	65.2%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.